S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine (original) (raw)

2001, The Journal of pharmacology and experimental therapeutics

Abstract

S33005 displayed marked affinity for native, rat, and cloned human serotonin (5-HT) transporters (SERT) and less pronounced affinity for norepinephrine (NE) transporters (NET), while its affinity at dopamine (DA) transporters and >50 other sites was negligible. Reuptake of 5-HT and (less potently) NE into cerebral synaptosomes was inhibited by S33005, whereas DA reuptake was little affected. In vivo, S33005 prevented depletion of cerebral pools of 5-HT by parachloroamphetamine. Furthermore, it decreased electrical activity of raphe-localized serotonergic neurones, an action abolished by the 5-HT1A antagonist WAY100,635. At higher doses, S33005 blocked firing of locus ceruleus-localized adrenergic neurones, an action abolished by the alpha2-adrenergic antagonist idazoxan. In contrast, S33005 did not inhibit ventrotegmental dopaminergic neurones. In frontal cortex of freely moving rats, S33005 dose dependently elevated dialysate levels of 5-HT, NE, and DA. In hippocampus, levels of...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (50)

  1. Be ´ı ¨que JC, de Montigny C, Blier P and Debonnel G (1999) Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 22:198 -211.
  2. Be ´ı ¨que JC, de Montigny C, Blier P and Debonnel G (2000) Effects of sustained administration of the serotonin and norepinephrine reuptake inhibitor venlafax- ine: I. In vivo electrophysiological studies in the rat. Neuropharmacology 39:1800 - 1812.
  3. Bervoets K, Rivet J-M and Millan MJ (1993) 5-HT 1A receptors and the tail-flick response. IV: Spinally-localized 5-HT 1A receptors postsynaptic to serotoninergic neurones mediate spontaneous tail-flicks in the rat. J Pharmacol Exp Ther 264: 95-104.
  4. Blanchard DC, Griebel G, Rodgers RJ and Blanchard RJ (1998) Benzodiazepine and serotonergic modulation of antipredator and conspecific defense. Neurosci Biobe- hav Rev 22:597-612.
  5. Blier P and de Montigny C (1999) Serotonin and drug-induced therapeutic responses in major depression, obsessive-compulsive and panic disorders. Neuropsychophar- macology 21:91S-98S.
  6. Borsini F and Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity ? Psychopharmacology 94:147-160.
  7. Caligiuri MP and Ellwanger J (2000) Motor and cognitive aspects of motor retarda- tion in depression. J Affect Disord 57:83-93.
  8. Cases O, Seif I, Grimsby J, Gaspar P, Chen K, Pournin S, Mu ¨ller U, Aguet M, Babinet C, Chen Shih J and De Maeyer E (1995) Aggressive behaviour and altered amounts of brain serotonin and norepinephrine in mice lacking MAOA. Science (Wash DC) 268:1763-1766.
  9. Connor TJ, Kelliher P, Harkin A, Kelly JP and Leonard BE (1999) Reboxetine attenuates forced swim test-induced behavioural and neurochemical alterations in the rat. Eur J Pharmacol 379:125-133.
  10. Connor TJ, Kelliher P, Shen Y, Harkin A, Kelly JP and Leonard BE (2000) Effect of subchronic antidepressant treatments on behavioural, neurochemical, and endo- crine changes in the forced-swim test. Pharmacol Biochem Behav 65:591-597.
  11. Cryan JF and Lucki I (1999) Reboxetine, a selective norepinephrine reuptake inhib- itor, alters active behaviours in a modified rat forced swim test. Behav Pharmacol 10 (Suppl):S20.
  12. Dekeyne A, Iob L and Millan MJ (2001) Following long-term training with citalo- pram, both mirtazapine and mianserin block its discriminative stimulus proper- ties in rats. Psychopharmacology 153:389 -392.
  13. Edwards DH and Kravitz EA (1997) Serotonin, social status and aggression. Curr Opin Neurobiol 7:812-819.
  14. Evenden J (1999) The pharmacology of impulsive behaviour in rats. V: the effects of drugs on responding under a discrimination task using unreliable visual stimuli. Psychopharmacology 143:111-122.
  15. Frazer A (1997) Antidepressants. J Clin Psychiatry 58:9 -25.
  16. Fuller RW, Wong DT and Robertson DW (1991) Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev 11:17-37.
  17. Harvey AT, Rudolph RL and Preskorn SH (2000) Evidence of the dual mechanisms of action of venlafaxine. Arch Gen Psychiatry 57:503-509.
  18. Hayashi Y and Maze M (1993) ␣ 2 -Adrenoceptor agonists and anaesthesia. Br J Anaesth 71:108 -118.
  19. Martin P, Soubrie ´P and Puech AJ (1990) Reversal of helpless behaviour by serotonin uptake blockers in rats. Psychopharmacology 101:403-407.
  20. Matsumoto K, Ohima K and Watanabe H (1995) Noradrenergic denervation atten- uates desipramine enhancement of aggressive behavior in isolated mice. Pharma- col Biochem Behav 50:481-484.
  21. Miczek K, Weerts E, Haney M and Tidey J (1994) Neurobiological mechanisms controlling aggression: preclinical developments for pharmacotherapeutic inter- ventions. Neurosci Biobehav Rev 18:97-110.
  22. Millan MJ, Gobert A, Girardon S and Dekeyne A (1999) Citalopram elicits a dis- criminative stimulus in rats at a dose selectively increasing extracellular levels of serotonin vs dopamine and noradrenaline. Eur J Pharmacol 364:147-150.
  23. Millan MJ, Lejeune F and Gobert A (2000a) Reciprocal autoreceptor and heterore- ceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents. J Psychophar- macol 14:114 -138.
  24. Millan MJ, Lejeune F, Gobert A, Brocco M, Auclair A, Bosc C, Rivet JM, Lacoste JM, Cordi A and Dekeyne A (2000b) S18616, a highly potent spiroimidazoline agonist at ␣ 2 -adrenoceptors: II. Influence on monoaminergic transmission, motor function, and anxiety in comparison with dexmedetomidine and clonidine. J Pharmacol Exp Ther 295:1206 -1222.
  25. Millan MJ, Newman-Tancredi A, Rivet JM, Brocco M, Lacroix P, Audinot V, Cistarelli L and Gobert A (1997) S15535, a novel benzodioxopiperazine ligand of serotonin (5-HT) 1A receptors: I. Interaction with cloned human (h)5-HT 1A , dopa- mine hD 2 /hD 3 and h␣ 2A -adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity. J Pharmacol Exp Ther 282:132-147.
  26. Mir S and Taylor D (1997) The adverse effects of antidepressants. Curr Opin Psychiatry 10:88 -94.
  27. Mitchell PJ and Redfern PH (1992) Chronic treatment with clomipramine and mianserin increases the hierarchical position of subdominant rats housed in tri- ads. Behav Pharmacol 3:239 -247.
  28. Muth EA, Moyer JA, Haskins JT, Andree TH and Husbands GEM (1991) Biochem- ical, neurophysiological and behavioural effects of WAY-45,233 and other identi- fied metabolites of the antidepressant venlafaxine. Drug Dev Res 23:191-199.
  29. Njung'e K and Handley SL (1991) Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice: a putative test for anxio- lytic agents. Br J Pharmacol 104:105-112.
  30. Papp M, Klimek V and Willner P (1994) Parallel changes in dopamine D 2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology 115:441-446.
  31. Pawlowski L and Nowak G (1987) Biochemical and pharmacological tests for the prediction of ability of monoamine uptake blockers to inhibit the uptake of nor- adrenaline in vivo: the effects of desipramine, maprotiline, femoxetine and citalo- pram. J Pharmacol 39:1003-1009.
  32. Piccinelli M, Pini S, Bellantuono C and Wildinson G (1995) Efficacy of drug treat- ment in obsessive-compulsive disorder. Br J Psychiatry 166:424 -443.
  33. Pigott TA and Seay SM (1999) A review of the efficacy of selective serotonin reuptake inhibitors in obsessive-compulsive disorder. J Clin Psychiatry 60:101-106.
  34. Popik P (1999) Preclinical pharmacology of citalopram. J Clin Pharmacol 19:4S-22S.
  35. Porter RJ, Hamish McAllister R and Young WAH (1999) Acute effects of venlafaxine and paroxetine on serotonergic transmission in human volunteers. Psychophar- macology 146:194 -198.
  36. Redrobe JP, Bourin M, Colombel MC and GB Baker (1998) Dose-dependent norad- renergic and serotonergic properties of venlafaxine in animal models indicative of antidepressant activity. Psychopharmacology 138:1-8.
  37. Re ´ne ´ric JP and Lucki I (1998) Antidepressant behavioural effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology 136:190 -197.
  38. Riva M, Brunello N, Rovescalli AC, Galimbert R, Carfagna N, Carminati P, Pozzi O, Ricciardi S, Roncucci R, Rossi A and Racagni G (1989) Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and bio- chemical studies. J Drug Dev 1:243-253.
  39. Sa ´nchez C and Meier E (1997) Behavioural profiles of SSRIs in animal models of depression, anxiety and aggression. Psychopharmacology 129:197-205.
  40. Schweizer E, Thielen RJ and Frazer A (1997) Venlafaxine, a novel antidepressant compound. Exp Opin Invest Drugs 6:65-78.
  41. Steru L, Chermat R, Thierry B, Mico JA, Lenegre A, Steru M, Simon P and Porsolt RD (1987) The automated tail suspension test: a computerized device which differentiates psychotropic drugs. Prog Neuropsychopharmacol Biol Psychiatry 11:659 -671.
  42. Teste JF, Pelsy-Johann I, Decelle T and Boulu RG (1993) Anti-immobility activity of different antidepressant drugs using the tail suspension test in normal or reser- pinized mice. Fundam Clin Pharmacol 7:219 -226.
  43. Thie ´bot MH, Martin P and Puech AJ (1992) Animal behavioural studies in the evaluation of antidepressant drugs. Br J Psychiatry 160:44 -50.
  44. Versiani M, Amin M and Chouinard G (2000) Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. Clin Psycho- pharmacol 20:28 -34.
  45. Von Voigtlander PF, Triezenberg HJ and Losey EG (1978) Interactions between clonidine and antidepressant drugs: a method for identifying antidepressant-like agents. Neuropharmacology 17:375-381.
  46. West CHK and Weiss JM (1998) Effects of antidepressant drugs on rats bred for low activity in the swim test. Pharmacol Biochem Behav 61:67-79.
  47. White SM, Kucharik RF and Moyer JA (1991) Effects of serotonergic agents on isolation-induced aggression. Pharmacol Biochem Behav 39:729 -736.
  48. Willner P (1991) Animal models as simulations of depression. Trends Pharmacol Sci 12:131-137.
  49. Willner P (1997) Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology 134:319 -329.
  50. Wong EHF, Sonders MS, Amara SG, Tinholt PM, Piercey MFP, Hoffmann WP, Hyslop DK, Franklin S, Porsolt RD, Bonsignon A, Carfagna N and McArthur RA (2000) Reboxetine a pharmacologically potent, selective, and specific norepineph- rine reuptake inhibitor. Biol Psychiatry 47:818 -829.